Brivaracetam
Phase 3Active 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Childhood Absence Epilepsy
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Trial Timeline
Jul 29, 2021 → Aug 24, 2026
NCT ID
NCT04666610About Brivaracetam
Brivaracetam is a phase 3 stage product being developed by UCB for Childhood Absence Epilepsy. The current trial status is active. This product is registered under clinical trial identifier NCT04666610. Target conditions include Childhood Absence Epilepsy, Juvenile Absence Epilepsy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (17)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03532516 | Pre-clinical | Active |
| NCT04666610 | Phase 3 | Active |
| NCT04882540 | Phase 1 | Completed |
| NCT04715646 | Phase 3 | Recruiting |
| NCT03685630 | Phase 3 | Completed |
| NCT03517423 | Pre-clinical | Completed |
| NCT03405714 | Phase 2 | Completed |
| NCT03250377 | Phase 3 | Completed |
| NCT01728077 | Phase 3 | Completed |
| NCT01710670 | Phase 1 | Completed |
| NCT01653262 | Phase 3 | Completed |
| NCT00422422 | Phase 2 | Completed |
| NCT01339559 | Phase 3 | Completed |
| NCT00761774 | Phase 3 | Completed |
| NCT00150800 | Phase 3 | Completed |
| NCT00175825 | Phase 2 | Completed |
| NCT00401648 | Phase 2 | Completed |
Competing Products
20 competing products in Childhood Absence Epilepsy